FC001
Cancer (unspecified)
Phase 1Active (Trial initiated 2024)
Key Facts
About FerroptoCure
A clinical-stage biotech developing ferroptosis-inducing drugs to treat cancer by targeting antioxidant pathways like xCT.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |